The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer.

Sung Hoon Sim; Bhumsuk Keam; Dong-Wan Kim; Tae Min Kim; Se-Hoon Lee; Doo Hyun Chung; Dae Seog Heo

首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer.

【24h】

The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer.

机译：吉非替尼剂量降低对表皮生长因子受体突变型非小细胞肺癌生存率的影响。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The patients experiencing gefitinib dose reduction or short-term treatment interruption due to toxicities did not show inferior survival, compared to those receiving full dose of gefitinib in NSCLC patients with EGFR mutation.

机译：与接受EGFR突变的NSCLC患者接受全剂量吉非替尼治疗相比，因毒性而接受吉非替尼剂量减少或短期治疗中断的患者生存率没有下降。

著录项

来源
《Journal of Cancer Research and Clinical Oncology 》 |2014年第12期| 共8页
作者
Sung Hoon Sim; Bhumsuk Keam; Dong-Wan Kim; Tae Min Kim; Se-Hoon Lee; Doo Hyun Chung; Dae Seog Heo;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer. [J] . Sung Hoon Sim, Bhumsuk Keam, Dong-Wan Kim, Journal of Cancer Research and Clinical Oncology . 2014 ,第12期

机译：吉非替尼剂量降低对表皮生长因子受体突变型非小细胞肺癌生存率的影响。
2. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment. [J] . Azuma K, Okamoto I, Kawahara A, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2012 ,第1期

机译：突变表皮生长因子受体蛋白的表达与非小细胞肺癌中突变特异性抗体测定的突变特异性抗体在吉非替尼治疗后的无进展存活中测定。
3. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment. [J] . Azuma K, Okamoto I, Kawahara A, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2012 ,第1期

机译：用吉非替尼治疗后，在非小细胞肺癌中用突变特异性抗体确定的突变表皮生长因子受体蛋白的表达与无进展生存的关联。
4. Development and validation of a radiomics nomogram for progression-free survival prediction in stage IV EGFR-mutant non-small cell lung cancer [C] . Jiangdian Song, Yali Zang, Weimin Li, Conference on Computer-Aided Diagnosis . 2017

机译：放射组学诺模图的开发和验证，用于IV期EGFR突变非小细胞肺癌的无进展生存期预测
5. Unanticipated Effects of Tyrosine Kinase Inhibitors on Vitamin D Receptor Expression and Gene Regulation In Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer. [D] . Timberlake, Alexandra F. 2017

机译：酪氨酸激酶抑制剂对表皮生长因子受体突变的非小细胞肺癌中维生素D受体表达和基因调控的意外影响。
6. Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors [O] . Clémentine Bouchez, Johan Pluvy, Ghassen Soussi, 2020

机译：表皮生长因子受体突变体非小细胞肺癌和脉络膜转移：长期结果和对表皮生长因子受体酪氨酸激酶抑制剂的反应
7. Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival after Gefitinib Treatment [O] . Azuma Koichi, Okamoto Isamu, Kawahara Akihiko, 2012

机译：非小细胞肺癌吉非替尼治疗后确定的突变特异性表皮生长因子受体蛋白的表达与非小细胞肺癌的突变特异性抗体的关联。

The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer.

摘要

著录项

相似文献

相关主题

期刊订阅